证券代码：002412 证券简称：汉森制药 公告编号：2023-013 湖南汉森制药股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 投资者依据提示，授权登入"汉森制药投资者关系"小程序，即可参与交流。 出席本次业绩说明会的人员有：公司董事长兼总裁刘正清先生、独立董事夏 劲松先生、董事会秘书兼财务总监戴江洪先生及相关工作人员。 敬请广大投资者积极参与。 湖南汉森制药股份有限公司 董事会 2023 年 05 月 12 日 湖南汉森制药股份有限公司（以下简称"公司"）第五届董事会第十九次会 议审议通过了《2022年年度报告及摘要》，并刊登在2023年04月29日的《证券 时报》《上海证券报》《中国证券报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）上。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年 05月19日（星期五）15：00至17：00时在"汉森制药投资者关系"小程序举行 2022年度网上业绩说明会。本次业绩说明会将采用网络远程的方式举行，投资 者可登陆"汉森制 ...

Financial Performance - The company's revenue for Q1 2023 was ¥250,177,963.58, representing a slight increase of 0.53% compared to ¥248,851,389.62 in the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was ¥55,067,482.18, reflecting a growth of 6.26% from ¥51,824,070.34 year-on-year[4]. - Total operating revenue for Q1 2023 was CNY 250,177,963.58, a slight increase of 0.53% compared to CNY 248,851,389.62 in Q1 2022[19]. - Net profit for Q1 2023 reached CNY 55,067,482.18, representing a growth of 6.4% from CNY 51,824,070.34 in the same period last year[20]. - The total comprehensive income for Q1 2023 was CNY 60,658,900.25, compared to CNY 49,185,657.62 in Q1 2022, marking a growth of 23.3%[21]. - Earnings per share (EPS) for Q1 2023 was CNY 0.1094, an increase from CNY 0.1030 in Q1 2022[21]. Cash Flow - The net cash flow from operating activities increased by 60.05% to ¥70,447,112.49, up from ¥44,016,378.08 in the previous year[4]. - Cash inflow from operating activities totaled CNY 294,293,986.89, up from CNY 249,825,439.23 in the previous year, indicating a growth of 17.7%[23]. - The net cash flow from financing activities increased by 106.61% to ¥63,703,622.63, compared to the previous year[11]. - The net cash flow from financing activities was ¥2,045,917.55, a recovery from -¥30,970,705.08 in the same quarter last year[24]. - Total cash outflow from operating activities amounted to ¥223,846,874.40, up from ¥205,809,061.15 in Q1 2022[24]. - The net cash flow from investing activities was -¥73,944,830.71, worsening from -¥12,597,750.87 year-over-year[24]. Assets and Liabilities - Total assets at the end of Q1 2023 reached ¥2,368,623,266.25, marking a 3.39% increase from ¥2,290,944,050.05 at the end of the previous year[4]. - The company's total assets as of March 31, 2023, amount to CNY 2,368,623,266.25, an increase from CNY 2,290,944,050.05 at the beginning of the year[17]. - Total current assets are reported at CNY 933,341,824.23, up from CNY 865,402,215.15 at the start of the year[17]. - The total liabilities amount to CNY 413,832,663.08, compared to CNY 396,812,347.13 at the beginning of the year[18]. - The company's cash and cash equivalents at the end of the reporting period are CNY 143,953,813.25, slightly down from CNY 145,405,613.92 at the beginning of the year[16]. - Accounts receivable stand at CNY 238,709,792.19, showing an increase from CNY 232,178,903.25 at the start of the year[16]. - The company has a total of CNY 240,313,858.24 in inventory, down from CNY 246,617,154.53 at the beginning of the year[17]. - The total equity attributable to shareholders grew by 3.20% to ¥1,954,790,603.17 from ¥1,894,131,702.92 at the end of the previous year[4]. - The total equity remains stable at CNY 1,954,790,603.17, unchanged from the previous reporting period[18]. Research and Development - Research and development expenses rose by 41.74% to ¥12,227,616.83, driven by increased investment in the development of new products[9]. - Research and development expenses increased to CNY 12,305,644.26, up 41.5% from CNY 8,682,027.43 in Q1 2022[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,707[13]. - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[13]. Other Income and Expenses - Other income increased by 142.29% to ¥1,520,860.75, primarily due to government subsidies received[9]. - The company reported a decrease in sales expenses to CNY 101,845,183.83 from CNY 105,570,433.08 in Q1 2022, reflecting a reduction of 3.4%[19]. - Tax payments increased to ¥34,303,087.48 from ¥26,719,717.24 year-over-year[24]. - The company paid ¥49,668,394.58 in employee compensation during the quarter, down from ¥56,186,649.20 in the previous year[24].

湖南汉森制药股份有限公司2022年年度报告全文 2022 年年度报告 证券简称：汉森制药 证券代码：002412 ...

Product Overview - The main product of Hunan Hansen Pharmaceutical Co., Ltd. is "Simotang," a traditional Chinese medicine aimed at improving gastrointestinal motility, primarily targeting newborns, postpartum women, and the elderly [3] - Other notable products include "Suquan Capsules" for treating urinary incontinence in the elderly and children, and "Ginkgo Leaf Capsules" for cardiovascular diseases, with the latter having a high content of active ingredients compared to competitors [3] Market and Sales - The sales distribution between hospital and OTC markets is approximately 30% and 70%, respectively [4] - Sales of Simotang have been adversely affected this year due to a challenging OTC environment, media events, and the suspension of the basic drug supplement directory in several provinces [4][5] - The company has entered 11 provinces for the basic drug supplement directory, but many have paused or rejected new entries, impacting sales growth in grassroots medical institutions [5] Research and Development - Currently, there are no new R&D products; the focus remains on enhancing existing products, particularly in gastrointestinal and cardiovascular medications [5] - The company has completed various stability tests and obtained patents for new formulations of Simotang, which will help protect intellectual property and improve market competitiveness [5] Financial Investments - The investment in Sanxiang Bank is part of a broader strategy to develop the pharmaceutical supply chain, including upstream herbal cultivation and downstream medical services [6] - The financial sector investment is expected to provide stable returns and support the company's overall growth strategy [6] Raw Material Costs - The prices of raw materials for the main products are stable, with no significant impact expected on profitability from rising prices of traditional Chinese medicine ingredients [6] Future Considerations - There is currently no clear direction from major shareholders regarding the future of Nanyue Pharmaceutical, which is undergoing GMP certification and has not resumed normal production [7]

Group 1: Company Overview and Strategy - The company focuses on traditional Chinese medicine and is expanding into health and rehabilitation sectors, emphasizing a combination of medical care and elderly care [3] - The health industry is a key development area for the company, with plans to integrate rehabilitation, health maintenance, and wellness [3][4] Group 2: Rehabilitation and Wellness Model - The company aims to create a high-end rehabilitation and wellness facility, differentiating itself from traditional nursing homes by offering more than just accommodation [4] - The chosen location for the facility is strategically placed between Yiyang and Changsha, providing convenient access and a pleasant environment [4] Group 3: Medical Partnerships and Resources - The company is targeting partnerships with secondary hospitals (Level II) and is open to collaborations with specialized departments and experts from major hospitals [5] - The company is developing a demonstration base for the cultivation of traditional Chinese medicinal herbs, focusing on resource integration rather than market monopoly [5] Group 4: Financial Investments and Risks - The company has invested over 400 million in the new South Yue Pharmaceutical plant, which has recently passed GMP certification [6] - Investment in Sanxiang Bank is aimed at supplementing profits and providing new financing channels, with funding sourced from internal funds and potential bank credit [6] Group 5: Market Performance and Sales Strategy - The market share of Si Mo Tang is currently 72% in OTC and grassroots medical institutions, while hospitals account for 28% [6] - The company has established a WeChat public account for brand promotion and is considering developing an app for direct sales in the future [6]

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | | 大禹资产管理有限公司 ...

Group 1: Company Overview and Strategic Direction - The company is focusing on the cultivation of traditional Chinese medicinal materials, primarily Zhiqiao, to meet raw material demands and respond to government policies [4] - The company aims to establish "Xiang Jiuwai" as a leading brand in the market [4] - Future plans include collaborating with influential hospitals in surrounding cities for health check-ups and rehabilitation services [4] Group 2: Market Challenges and Sales Performance - The sales of Si Mo Tang have not met expectations due to several factors, including a challenging OTC environment, media events affecting consumer perception, and the suspension of basic medicine inclusion in various provinces [6] - In 2014, approximately 70% of Si Mo Tang's revenue came from OTC sales, which has been significantly impacted [6] - Sales in Hunan have remained flat this year, with some progress in market expansion in Xiangnan and Xiangxi regions [6] Group 3: Investment and Financial Planning - The company is gradually advancing its investment in the health industry, with a focus on feasibility studies for medical services [5] - The investment amount for new projects will be determined based on the company's capacity [5] - The company has previously published a feasibility study report on the cultivation of medicinal materials [5] Group 4: Acquisition and Market Positioning - The company continues to prioritize acquisitions as a key strategy, given the lengthy and costly process of developing new traditional Chinese medicines [8] - The integration of Yongzitang's sales has faced challenges, but improvements are being made as stakeholders understand the long-term benefits [7] - Yongzitang's sales were projected to reach 200 million, but this target was not met due to price adjustments and the overall OTC environment [7] Group 5: Regulatory and Compliance Issues - Yongzitang's products have been included in the medical insurance directory in thirteen provinces, with hopes for national coverage [8] - The company is actively working on pricing adjustments and tendering processes to align with market standards [8] - The future handling of the major shareholder's asset, Nanyue Pharmaceutical, remains uncertain as it is undergoing GMP certification [8]

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2015-003 | --- | --- | --- | |--------------------|------------------------|----------------------------| | | √ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 广发资管 | 毛丁丁 | | 人员姓名 | 红塔红土 | 谭权胜 | | | | | | | 彤源投资 | 谷玺 | | | 海通资管 | 刘彬 | | | SMC 基金 | 王帅 | | | 国都证券 | 赵玥 | | | 中信产业基金 | 陈宇 | | | 坚木投资 | 刘晓霞、刘彬阳 | | | 国都资管 | 姚巍 | | | 中欧博瑞 | 汪洋、张宪强 | | | 泰康人寿 | 殷萌萌 | | | 中欧基金 | 龙宇飞 | 1 | --- ...

Group 1: Company Development and Strategy - The future direction of Hansen Health Industry includes standardized planting of traditional Chinese medicinal materials and integration of medical and health services [4] - The company is focusing on investing in unique traditional Chinese medicine formulation enterprises and seeking good hospital platforms, as well as considering retail pharmacy chain investments [4][5] - The company will not abandon its investment plans in women's and children's hospitals, despite current policy restrictions [5] Group 2: Sales and Marketing - The company has shifted from a product-centric division system to a market-oriented marketing channel system, enhancing clarity in responsibilities and stability in organizational structure [5] - The acquisition of Yongzitang was aimed at diversifying product offerings and mitigating risks associated with a limited product range [6] Group 3: Financial Performance and Challenges - The company's 2016 performance forecast is cautious due to increased depreciation, reduced bank interest income, rising marketing expenses, and adverse macroeconomic factors such as national medical insurance cost control and declining tender prices [6] - The company is facing challenges in the bidding process due to declining local tender prices, but maintains a price floor for its products [6][7] Group 4: Investment and Banking - The company is actively involved in the establishment of Sanxiang Bank, which is expected to provide new profit growth points and funding support for future investments [7]

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2016-002 | --- | --- | --- | |--------------------|-----------------------------------|----------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 吴学贵 | | | 人员姓名 | 周光华 | | | | 黄子生 | | | | 吴丁杰 | | | | 雷志鹏 | | | | 邓彬城 | | | | 张颖国 | | | | 李智雄 | | | | 黄国权 | | | | 陈少仲 | | | | 蔡丽 | | | | 梁亚玲 | | 1 | --- | --- | |-----------------------------|----------------------- ...